Is InterCure Ltd. (INCR) a Buy, Sell, or Hold?
NASDAQ : INCR
InterCure Ltd. — News
$0.97 USD
$0.03 (3.11%)
- Volume
- 23K
- Average Volume
- 50.94K
- Market Capitalization
- $55.44M
- P/E Ratio
- -4.01
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $1.77
- Year Low
- $0.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.48
| Source | Headline |
|---|---|
|
InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
NEW YORK & HERZLIYA, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company”), today announced that, further to the Company's prior reports regarding growing demand in Germany and opportunities arising from the recent U.S. federal rescheduling of cannabis, the Company has entered into a binding term sheet providing for funding commitments of NIS 22 million (approximately US$7.4 million), which may increase to NIS 54 million (approximately US$18.6 million) (the “Private Placement”). globenewswire.com - 2026-06-22 08:50:00 |
|
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U. S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U. S. Medical Cannabis Markets. globenewswire.com - 2026-06-15 09:25:00 |
|
InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
First Tranche Closing (50%) of Botanico Transaction Expands International Platform with Exclusive Access to U.S. Genetics, Premium Brands and Advanced AI-Driven Technologies; Company Reports Growing Demand in Germany and Evaluates Opportunities in Regulated U.S. Medical Cannabis Markets. globenewswire.com - 2026-06-15 09:25:00 |
|
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events globenewswire.com - 2026-04-30 18:05:00 |
|
InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
The Company reported over NIS 270 million in revenue, NIS 37 million in Net loss, NIS 47 million in Adjusted EBITDA and NIS 17 million in positive operating cash flow, reflecting strong resilience and consistent profitability, with a twelfth consecutive half-year of positive Adjusted EBITDA, as the Company continues to recover from the impact of the October 7, 2023 events NEW YORK and HERZLIYA, Israel, April 30, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. globenewswire.com - 2026-04-30 18:05:00 |
